Too much women’s health research dies before it even leaves the lab.

On one side: biotech investors focused on billion-dollar plays and decade-long timelines. On the other: femtech investors backing consumer apps without the appetite for deep science.

But AthenaBIO‘s new spin-out AthenaBIO wants to bridge that gap - carrying breakthrough discoveries across the ‘valley of death.’

As founder Laura Minquini explains:

“The reason this is not making it out of the lab is not for a lack of science. It’s for a lack of capital.”